Key result
Coexisting ASCVD and stroke mortality falls ~3.5% annually among US adults from 1999 to 2025.
Observational (n=876,383)
Yes
Answers are grounded in this paper and cite their sources.
Although U.S. mortality involving coexisting ASCVD and stroke fell by ~59% between 1999 and 2025, progress was interrupted between 2018 and 2021, reversed among adults aged 25–44 after 2015, and remains marked by persistent racial, sex, and geographic disparities.
Background ASCVD and stroke remain leading causes of death in the United States, sharing overlapping risk factors and clinical consequences. Long-term declines in vascular mortality have slowed while disparities persist. We evaluated national trends and disparities in mortality involving coexisting ASCVD- and stroke-related conditions among U.S. adults from 1999 to 2025. Methods We performed a retrospective population-based study using the CDC WONDER Multiple Cause of Death database. Adults aged ≥25 years were included. Deaths were identified when prespecified ASCVD-related and stroke-related ICD-10 codes were both documented on the same death certificate, whether as underlying or contributing causes. The outcome represents a death-certificate-defined mortality phenotype rather than clinically adjudicated concurrent disease. Age-adjusted mortality rates (AAMRs) per 100,000 were calculated using the 2000 U.S. standard population. Trends were assessed overall and by sex, age group, race/ethnicity, census region, urbanization, and state. Urbanization analyses were restricted to 1999–2020. Sensitivity analyses included restriction to atherosclerotic-specific codes (I25.x) and exclusion of provisional 2025 data. Results A total of 876,383 deaths were identified. Overall average AAMR was 15.01 per 100,000. Mortality declined from 26.82 in 1999 to 10.91 per 100,000 in 2025, with an AAPC of −3.53% (95% CI, −4.27 to −2.78; p < 0.001). After sustained declines through 2018, AAMR showed a borderline significant increase during 2018–2021 (APC: 6.06%; 95% CI, 0.01–12.48; p = 0.050), not replicated under stricter cause-of-death definitions, followed by renewed decline from 2021 to 2025 (APC: −2.85%; 95% CI, −4.58 to −1.09; p = 0.004). Mortality burden remained higher among men, older adults, Black individuals, residents of the South, and non-metropolitan populations. Adults aged 25–44 years showed a significant increase after 2015, though absolute rates remain low and this finding warrants cautious interpretation. Conclusion Although mortality involving coexisting ASCVD- and stroke-related conditions declined substantially from 1999 to 2025, this progress was interrupted by a borderline reversal in the pandemic period and remained marked by persistent disparities. These findings support the need for stronger and more equitable prevention strategies, particularly for younger adults and high-burden populations and regions.
No takes yet. Share an insight, caveat, or question.
Mazhar et al. (2026) conducted an observational in Mortality involving coexisting atherosclerotic cardiovascular disease (ASCVD) and stroke-related conditions (n=876,383). Coexisting ASCVD- and stroke-related conditions over calendar time (1999–2025) vs. Baseline year (1999) and demographic/geographic subgroups was evaluated on Age-adjusted mortality rate (AAMR) per 100,000 population involving coexisting ASCVD- and stroke-related conditions (AAPC -3.53%, 95% CI -4.27 to -2.78, p=<0.001). Age-adjusted mortality involving coexisting ASCVD and stroke among U.S. adults declined from 26.82 to 10.91 per 100,000 between 1999 and 2025.
Synapse has enriched 10 related papers. Consider them for comparative context: